Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Gene TechnologyASX:BGT EV-to-OCF is -2.56 as of Aug. 19, 2026. The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, Bio-Gene Technology ranks worse than 52.27% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Bio-Gene Technology's Enterprise Value is A$6.70 Mil.
Bio-Gene Technology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.62 Mil. Therefore, Bio-Gene Technology's EV-to-OCF for today is -2.56.
The historical rank and industry rank for Bio-Gene Technology's EV-to-OCF or its related term are showing as below:
ASX:BGT'
s EV-to-OCF Range Over the Past 10 Years
Min: -20.77 Med: -4.49 Max: 0.09
Current: -3.23
During the past 8 years, the highest EV-to-OCF of Bio-Gene Technology was 0.09. The lowest was -20.77. And the median was -4.49.
ASX:BGT's EV-to-OCF is ranked worse than 52.27% of 1408
companies
in the Biotechnology industry
Industry Median: -3.66
vs ASX:BGT: -3.23
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio-Gene Technology's PE Ratio (TTM) for today is calculated as:
Bio-Gene Technology's share price for today is A$0.018.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio-Gene Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bio-Gene Technology EV-to-OCF Related Terms
Bio-Gene Technology EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Bio-Gene Technology's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Gene Technology's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gene Technology EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Bio-Gene Technology's EV-to-OCF falls into.
Bio-Gene Technology's current Enterprise Value is A$6.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio-Gene Technology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Gene Technology (ASX:BGT) has a EV-to-OCF of -2.56 as of Aug. 19, 2026. According to the industry distribution chart, Bio-Gene Technology ranks #736 out of 1408 companies in the Biotechnology industry, placing it in the top 52.3%.
Is Bio-Gene Technology's EV-to-OCF too high?
Bio-Gene Technology's current EV-to-OCF is -2.56. Based on the distribution chart, Bio-Gene Technology ranks #736 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint.
How does Bio-Gene Technology's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #736 out of 1408 companies for EV-to-OCF. This places Bio-Gene Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Bio-Gene Technology's current EV-to-OCF is -2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current EV-to-OCF of -2.56. The current EV-to-OCF is -2.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current EV-to-OCF is -2.56 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BGT has been successfully added to your 
